research grant

BioMark Diagnostics has been collaborating on the test with the Metabolomics Innovation Centre at the University of Alberta since early 2015.

The firm has signed a three-year agreement with the University Hospital of Zurich to develop the test for use in kidney transplant recipients.

The contract was awarded under DARPA's Detect It with Gene Editing Technologies program, which aims to create a device to detect at least 10 pathogens.

Earlier this year, Novigenix and collaborators were awarded up to €1 million to develop a blood-based multi-omics colorectal cancer assay.

The funding will help the company further develop its INSPECTR molecular diagnostic platform into a test that can be used in various settings.

Other grant recipients include scientists from the University of Chicago, UCLA, UC Santa Barbara, and the University of Washington.

The two grants awarded will support DiamiR's development of microRNA diagnostics for mild cognitive impairment, Alzheimer's disease, and Rett syndrome.

The project, coordinated by Jena University Hospital and expected to run for five years, aims to address resistance mechanisms in Gram-negative pathogens.